Cormark Has Pessimistic Outlook of Curaleaf FY2024 Earnings

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Investment analysts at Cormark cut their FY2024 earnings estimates for Curaleaf in a report issued on Thursday, November 7th. Cormark analyst J. Pytlak now expects that the company will post earnings of ($0.27) per share for the year, down from their previous forecast of ($0.25). Cormark currently has a “Hold” rating on the stock. The consensus estimate for Curaleaf’s current full-year earnings is ($0.24) per share. Cormark also issued estimates for Curaleaf’s FY2025 earnings at ($0.19) EPS.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.25 price objective on shares of Curaleaf in a research note on Thursday, August 8th.

Curaleaf Stock Down 5.5 %

Shares of CURLF opened at $2.13 on Monday. The company has a market capitalization of $1.38 billion, a PE ratio of -7.34 and a beta of 0.86. The stock’s 50-day moving average price is $2.97 and its two-hundred day moving average price is $3.79. The company has a current ratio of 1.09, a quick ratio of 0.50 and a debt-to-equity ratio of 0.83. Curaleaf has a 12 month low of $2.07 and a 12 month high of $6.40.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.